Bioavailable testosterone is independently associated with Fatty Liver Index in postmenopausal women
More details
Hide details
Submission date: 2016-11-25
Final revision date: 2017-01-31
Acceptance date: 2017-02-14
Online publication date: 2017-07-19
Publication date: 2017-08-18
Arch Med Sci 2017;13(5):1188–1196
Introduction: Previous studies have examined the correlation between hyperandrogenemia and non-alcoholic fatty liver disease (NAFLD) in women and showed contradictory results. Therefore, we aimed to evaluate the relationship between testosterone level and Fatty Liver Index (FLI), as a surrogate marker for NAFLD, in a cohort of postmenopausal women.
Material and methods: A total of 150 postmenopausal women were included in this cross-sectional study. Anthropometric and biochemical parameters, as well as blood pressure, were obtained. Non-alcoholic fatty liver disease is assessed by FLI, an algorithm based on body mass index, waist circumference, triglycerides and -glutamyl transferase, as a simple and accurate predictor of hepatic steatosis. Women were divided into three groups (FLI < 30, n = 80; 30 ≤ FLI < 60, n = 44; FLI ≥ 60, n = 26). Homeostasis model assessment of insulin resistance (HOMA-IR) as a surrogate marker of insulin resistance was calculated.
Results: Multiple linear regression analysis revealed that the best model consisted of 4 parameters (e.g., bioavailable testosterone ( = 0.288, p = 0.001), log HOMA-IR ( = 0.227, p = 0.005), log high-sensitivity C-reactive protein ( = 0.322, p < 0.001), and retinol-binding protein 4 ( = 0.226, p < 0.001)]. Adjusted R2 for the best model was 0.550, which means that as much as 55.0% of variation in FLI could be explained with this model.
Conclusions: Bioavailable testosterone is independently associated with FLI in postmenopausal women.